Pharmacopsychiatry 2024; 57(02): 87-88
DOI: 10.1055/s-0044-1779561
Abstracts │ XVth Symposium of the Task Force Therapeutic Drug Monitoring of the AGNP
Lecture Abstracts

The value of therapeutic drug monitoring in the development of and treatment with long-acting injectable antipsychotics

C. U. Correll
1   Zucker School of Medicine at Hofstra/Northwell, New York, USA, and Charité – University Medicine, Berlin, Germany
› Institutsangaben
 

The development and therapeutic application of long-acting injectable antipsychotics (LAIs) represent a significant advancement in the management of psychiatric disorders. In the developmental context, TDM emerges as an indispensable tool, guiding researchers in optimizing pharmacokinetics and ensuring the efficacy and safety of these novel formulations.

Narrative review of the value and limitations of TDM for the development of and treatment with LAIs using recent examples of the successful use of pharmacokinetic data modeling, population pharmacokinetics and bridging for LAIs of different injection intervals that gained regulatory approval.

Throughout the developmental phase of LAIs, TDM enables the precise measurement of drug concentrations, facilitating the establishment of optimal dosing regimens for sustained therapeutic effects. By integrating TDM data into pharmacokinetic modeling, researchers gain insights into the complex interplay of drug metabolism, absorption, and distribution, thereby refining LAIs to achieve consistent and prolonged therapeutic levels. In the realm of ongoing treatment, TDM continues to play a pivotal role in personalized patient care. Regular monitoring of drug concentrations aids clinicians in tailoring dosages to individual needs, optimizing therapeutic outcomes, and preventing under- or over-dosing. The significance of TDM in real-world scenarios is supported by data indicating that several factors translate into different blood level and clinical results, including patient and illness variability, concomitant medications, and lifestyle that can impact drug metabolism, necessitating an adaptive and personalized treatment approach.

By bridging the gap between research and patient care, TDM emerges as a key facilitator in advancing the precision and efficacy of LAI treatments, ultimately contributing to improved outcomes and quality of life for individuals living with psychiatric disorders



Publikationsverlauf

Artikel online veröffentlicht:
12. März 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany